Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EAN 2026 | Real-world insights into chronic inflammatory demyelinating polyneuropathy management

Name: Real-world insights into chronic inflammatory demyelinating polyneuropathy management
Uploaded: 2026-06-28T00:00:00Z
Duration: 3 min 8 s

Franz Felix Konen • 28 Jun 2026

EAN 2026

Neuromuscular Disorders Antibodies Azathioprine Bortezomib Ciclosporin Dexamethasone Methotrexate Methylprednisolone Mycophenolate Rituximab

Franz Felix Konen, MD, PhD, Hannover Medical School, Hannover, Germany, discusses findings from a multicenter analysis of chronic inflammatory demyelinating polyneuropathy (CIDP) management across specialized German centers. He highlights considerable variation in treatment strategies compared with guideline recommendations, with IVIg and glucocorticoids remaining the most common first-line therapies. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.